ArticlePostepy dermatologii i alergologii2025
Apoptosis and PTX3 in lichen planus.
Article in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lichen planus (LP) is considered a T cell-mediated autoimmune disease although its aetiology remains unknown. Cytotoxic T cells play a central role in the pathogenesis of LP and these cells are known to significantly induce apoptosis in basal keratinocytes. Aim: To correlate pentraxin 3 (PTX3) with apoptosis in basal cell keratinocytes in LP and to determine whether it is a marker in this disease. Material and methods: Inclusion criteria were as follows: (i) providing written consent for participation, (ii) presence of typical clinical findings (livid-red, violaceous, flat-topped polygonal papules and plaques, fern appearance in the oral mucosa, flexural involvement, and Wickham's striae) and (iii) histopathological confirmation of LP. Results: A total of 60 participants, 30 patients and 30 controls, were included in the study. No difference was found between groups in terms of age and gender. There was a significant difference in PTX3 levels between groups. As to patients with LP, 21 (70%) patients had skin involvement only, 2 (6.7%) patients had mucosal involvement only, and 7 (23.3%) patients had both skin and mucosal involvement of LP. Conclusions: PTX3 may be associated with apoptosis in LP. Although there are no data on the usability of PTX3 as a specific marker of LP, the present study aimed to demonstrate its usability as a marker of active LP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.